Everything started with Pr. Harry Sokol (Professor at the Gastroenterology department of the Saint Antoine Hospital) and his observations on patients. After comparing the gut microbiome from Inflammatory Bowel Diseases (IBD) patients and healthy subjects, he and his team identified our star bacterium Faecalibacterium prausnitzii as a key player of our health. In other words, they discovered that patients suffering from inflammatory bowel diseases simply do not have the microbiome it takes to fight their conditions. That was a new dawn in this field of inflammatory bowel diseases and in the field of microbiome.
Pr. Sokol then partnered with Dr. Philippe Langella’s team (Research Director at the French National Institute of Agricultural Research) to study the yet unexplored anti-inflammatory properties of Faecalibacterium prausnitzii. Together, they managed to isolate and select the right strain to initiate the work on a new type of drug candidates.
Pr. Patrick Gervais (Emeritus Professor of Process Engineering at AgroSup Dijon) brought his world-renowned expertise in the development of extremely-oxygen sensitive bacteria to the mission. Together, the team joined forces to take up the challenge of growing such fastidious strains in a robust manner, which is the next frontier in the field of microbiome-based therapeutics. We were the first to cross it.A 7-million Series A funding was raised in 2018 to jump start the journey and more than 15 million euros have been secured since then to fuel in our lead program EXL01, build a state-of-the-art manufacturing pilot unit and develop our pipeline..
After years spent developing our therapeutic solution, we are coming back to where it all started, the patients, for our first clinical trial.
we will cross the next frontier
to give patients,
a fair chance to fight.
Oops! Something went wrong while submitting the form.